Vemlidy

Tenofovir alafenamide fumarate tablets (Vemlidy) is a nucleoside analog reverse transcriptase inhibitor (NRTI) that inhibits viral replication by inhibiting the reverse transcriptase activity of hepatitis B virus (HBV) and blocking the extension of viral DNA chains.

Drug name

Common name: Tenofovir Alafenamide Fumarate Tablets
Trade name: Vemlidy®
Other names: TAF

Indications

Indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Specifications and characteristics

25 mg/tablet, yellow round film-coated tablet, engraved with "GSI" on one side and "25" on the other side.

Main ingredients

Active ingredient: tenofovir alafenamide (equivalent to 28 mg fumarate)
Excipients: croscarmellose sodium, lactose monohydrate, etc.

Usage and dosage

Standard dosage: 25 mg once daily, with food
How to take: Swallow the tablet whole, do not break or chew it

Dose adjustment

1. Missed dose: Take it immediately as soon as you notice it. If it is close to the next dose time, skip it
2. Renal insufficiency: No adjustment is required for creatinine clearance ≥15mL/min. Use is not recommended for end-stage renal disease (<15mL/min)
3. Hepatic insufficiency: No adjustment is required for Child-Pugh class A, and not recommended for decompensation (class B/C)

Precautions when using medication

1. Pre-medication testing: HIV infection must be screened, and HIV-infected patients need to be combined with antiviral treatment
2. Monitoring requirements:
Regular testing of renal function (creatinine, serum phosphorus, etc.) before and during medication
Continuous monitoring of liver function for several months after discontinuation of medication (may cause acute exacerbation of hepatitis B)
3. Special warning:
Be wary of lactic acidosis/hepatic steatosis (manifested by fatigue, dyspnea, etc.)

Avoid combined use with potent P-gp inducers (such as rifampicin, St. John's wort)

Drug use for special groups

Pregnant women: Weigh the pros and cons (Pregnancy Registration Number 1-800-258-4263)
Lactation: Safety is unknown, it is recommended to suspend breastfeeding
Children: Safety not established for under 18 years old
Elderly: No dose adjustment required, but renal function needs to be monitored

Adverse reactions

Common (≥5%): headache, abdominal pain, fatigue, cough, nausea, back pain
Serious adverse reactions: lactic acidosis, acute exacerbation of hepatitis B, renal damage

Contraindications

There are no absolute contraindications, but it is contraindicated in patients with end-stage renal disease and decompensated cirrhosis

Drug interactions

1. Contraindicated combination: Strong P-gp inducers (such as carbamazepine, rifampicin)
2. Use drugs with caution: nephrotoxic drugs (such as NSAIDs, aminoglycosides)
3. Safe combination: No significant interaction has been found with sofosbuvir/velpatasvir

Storage method

1. Temperature: Below 30°C (86°F)
2. Packaging: Keep the original packaging sealed and protected from light
3. Expiration: Pay attention to the validity period